SUMMARY A double-blind controlled clinical trial of crossover design was conducted in 26 volunteers suffering from migraine. Of 20 subjects who completed the trial, 16 had fewer attacks on amitriptyline than on placebo. Amitriptyline was found to have the greatest effect in reducing attacks with a short warning and in which no specific cause could be recognized. It had least effect in attacks with a long warning and recognized as due to fatigue. The drug was effective only in reducing those attacks with shorter duration and its effect was irrespective of severity. A dosage of between 10 and 60 mg, usually taken at night, was found to be adequate.
Amitriptyline has been found effective in chronic tension headache (Lance and Curran, 1964) and its beneficial use in migraine has been reported (Friedman, 1968; Mahloudji, 1969) .
Although its precise mode of action in migraine is uncertain, amitriptyline and the tricyclic antidepressants possess similarities in structure and pharmacological effect to some of the recently introduced prophylactic agents used in this condition.
SELECTION OF SUBJECTS
Volunteers were requested via the British Migraine Association and the press. The criteria of migraine used was the presence of intermittent headache with at least three of the following features: unilateral distribution, sensory prodromata, associated nausea; photophobia and throbbing.
All subjects were asked to keep a record of their migraine attacks. These showed the information listed in Table 1 . The charts were returned and discussed every two months with a statement as to their accuracy. It was indicated that attacks causing no disturbance of daily routine should be recorded as mild; those causing some lack of efficiency as moderate, and those causing complete disruption of usual activities should be recorded as severe.
Of 114 volunteers, 94 were excluded as follows. Seventy-five were excluded before or during a 26 week control period. Only those subjects having more than two attacks per month and with over 50% described as at least of moderate severity were Disease and Blindness (1962) . Differences were tested for significance using chisquared.
RESULTS
Sixteen out of 20 subjects had fewer attacks when Total attacks were reduced from 356 on 2 placebo to 207 on amitriptyline, a reduction of 2 42% (P<0-001) (Table 7) .
Attacks were classified as having no warning, 1 ' a warning of less than six hours, and a warning of more than six hours. The proportion of attacks ____ in each of these categories was not significantly 20 20 changed by amitriptyline therapy. There was, however, a difference of the effect of amitriptyoubject on placebo also line which caused a significant decrease for .ddition to the principal attacks with no warning or a short warning, and of increased headaches no significant improvement for attacks with a warning of longer than six hours (Table 8) . Attacks with a duration of less than 24 hours showed a significant decrease with amitriptyline, though this was not better than the average effect of the drug on all attacks. The drug had no significant effect, however, on attacks of longer duration (Table 9) .
Both with placebo and amitriptyline, attacks were most frequent in the early morning, declining progressively towards the evening. The drug produced the greatest percentage reduction for those attacks which occurred in the late evening (Table 10) .
Where the severity of the attacks was concerned, there was a significant decrease in attacks for each degree of severity, but the effect was not different from the average effect of the drug for all attacks. Amitriptyline thus reduced the number of attacks irrespective of degree (Table  11) . Classifying attacks according to the three reported associated features of depression, nausea, and photophobia, the drug was found to produce a smaller proportion of attacks with associated depression than did the placebo. The decrease was not, however, quite significant at the 5%0 level ( causes were classified into six categories: no specific cause, weather, psychological stress, food or drink, menstruation, and fatigue.
Amitriptyline had its greatest effect on attacks with no specific cause, the reduction being twofold. For attacks recognized as due to other causes, the reduction with amitriptyline was not significant and was least for those attacks attributed to fatigue (Table 13) .
When attacks during the period on placebo were compared with those during the control period of equal duration, a slight increase of attacks by 11 subjects when on placebo was shown, which did not reach a significant level. The placebo significantly reduced attacks due to psychological stress, though attacks with no specific cause were significantly increased, as were those occurring in the early morning. There were no significant differences for other classifications (Table 14) . follow-up period. Lance, Anthony, and Somerville (1970) found that Pizotifen (BC 105) produced improvement in 500o of subjects. Arthur and Hornabrook (1971) found that this drug gave a 500 % reduction in headaches in 400 % of their subjects. Dalsgaard-Nielsen (1968) showed improvement in 66% of cases taking Antaminic Substance (B.P. 400 Sandoz) with 36%, considerably improved. The method of selecting subjects gave a population well motivated to persist with regular therapy and which suffered slightly less severe migraine than the subjects chosen for some of the above trials. Although the subjects may have had greater psychological problems-and therefore be expected to respond to amitriptylinethere was no clinical evidence of depression, and all the patients continued in their normal occupations throughout the trial.
The method of recording attacks is suitable only for those who are intelligent and well motivated but has advantages over subjective estimates of improvement. Two of the subjects who had more attacks on amitriptyline reported that they felt considerably better, which was later not confirmed on their charts. The method of recording symptoms also allows elimination of headaches which are not migraine attacks, which was noted as a problem by Weissman (1971) . However, it was necessary to disregard only three headaches of a non-migrainous nature in this study.
Plasma levels of tricyclic drugs have been shown to vary considerably in subjects taking the same dose (Braithwaite, Goulding, Theano, Bailey, and Coppen, 1972) . There is also a considerable positive correlation between the plasma level and subjective side-effects (Asberg, Cronholm, Sjoqvist, and Tuck, 1970) . In this present study, variation of dosage was allowed in each subject. The dose finally selected was one which produced no appreciable side-effects. It is very likely that greater improvement in migraine would have resulted if a higher dose had been encouraged in the face of initial sideeffects, which have been shown to diminish after a few weeks of therapy. It may be that a reason for this drug not previously finding favour as a migraine prophylactic is that migraine sufferers are particularly subject to unpleasant side-effects if given the usual recommended starting dose of 75 mg daily. The drug appeared to have its maximum effect after several weeks of therapy, indicating the need for the relatively long period on each preparation. In most cases, in the present trial, this could have been due to modifications in dosage occurring at the start of treatment.
No explanation is evident for the selective effect of the drug on attacks of shorter warning and shorter duration. Further research on the action of prophylactic drugs on particular types of attack would be of interest. It is possible that the greater reduction of morning and evening attacks could be related to serum levels of the drug, the maximum dose of which was taken by most patients in the evening. The lack of a selective effect on either mild or severe attacks is in contrast with the findings of Arthur and Hornabrook (1971) with Pizotifen, which exerted its effect particularly on the more severe attacks.
There is a clear distinction between the marked effect of the drug on attacks not due to recognizable cause and those where the cause could be more clearly defined, particularly those associated with fatigue. Migraine is postulated to be a reaction to a variety of causal agents and it is possible that the drug had a mitigating effect on attacks by causal agents which may provoke a less vigorous response. One patient who was completely headache free on the drug reported having slight prodromal symptoms in response to his usual. and for him possibly the most potent, provoking stimuli.
A number of possibilities have been put forward as to the mode of action of prophylactic agents in migraine. Plasma serotonin level has been found to drop sharply at the onset of migraine headache and remain at a low level throughout the attack (Curran, Hinterberger, and Lance, 1965) . Serotonin was shown to constrict scalp arteries (Lance, Anthony and Gonski, 1967) , and it was postulated that methysergide may act in migrainous subjects by maintaining extracranial vasoconstriction on occasions when plasma serotonin falls (Lance, Anthony, and Somerville, 1970) . Tricyclic antidepressants have been shown to increase serotonin levels in the rat brain but only in high dosage (Kivalo, Rinne, and Karinkanta, 1961) . It is possible, however, to postulate firstly that the tricyclic drug blocks the uptake of serotonin into various tissues, especially the mast cells, and thereby increases circulating levels.
Other observations, however, suggest that these drugs inhibit the re-uptake from the extracellular space into the nerve ending of constrictor substances such as noradrenaline, which are released as the transmitter substance on nerve stimulation (Glowinski, Axelrod, and Iversen, 1966) . A similar effect was shown to take place in peripheral tissues as well as in the brain (Carlsson and Waldeck, 1965 The only hint of such a problem during the trial were two subjects who suffered from raised blood pressure. The first was a man aged 50 years who had an initially raised blood pressure of 160/105 mm Hg. He had been on amitriptyline therapy for 24 weeks when he complained of dizziness. His blood pressure was found to be 210/110 mm Hg but it was agreed that he should complete the trial. The other subject was a 44 year old lady who had no initial hypertension but complained of depression and increased headaches a week after the change from amitriptyline to placebo. Her blood pressure was found to be 150/100 mm Hg and again it was agreed that the trial should continue. The role of amitriptyline in the occurrence of the hypertension is uncertain. In both cases the blood pressure reverted to initial levels with conservative measures though in neither case was amitriptyline continued beyond the time necessary for completion of the trial. In all other cases there was no change in blood pressure.
The range of prophylactic agents used in migraine is increasing Amitriptyline as a wellknown drug for the treatment of depression may, in lower dosage, be useful for migraine sufferers who respond unsatisfactorily to other preparations. Decisions about therapy in a particular patient must obviously take into consideration the severity of the migraine, response to other drugs, and the unknown long-term effects of newer prophylactic agents, many of which are related in structure to the tricyclic antidepressants.
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